Medical Doctor Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Robert Redfield

Infectious Disease Baltimore, MD Medical Doctor

NPI 1568402717 CMS profile 464685

22 S Greene St, Baltimore, MD 21201

Open in the dashboard

General payments

$778,508

38 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Robert Redfield of Baltimore, MD is reported in the CMS Open Payments database as having received $778,508 across 38 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $98,387 6
2023 General $320,121 17
2022 General $280,000 12
2021 General $80,000 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Redfield
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Robert Redfield were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Robert Redfield Infectious Disease median Middle half National median
2019 $0 $190 $60–$862 $163
2020 $0 $124 $32–$606 $114
2021 $80,000 $148 $38–$905 $132
2022 $280,000 $166 $50–$834 $149
2023 $320,121 $171 $57–$787 $160
2024 $98,387 $176 $52–$752 $164
2025 $0 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Roche Diagnostics Corporation $638,387 30 payments
  2. Novavax Inc $140,000 7 payments
  3. Gilead Sciences, Inc. $121 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Consulting Fee $778,387 37 payments
  2. Food and Beverage $121 1 payment
Products named General payments · program years 2021–2024
  1. NOVAVAX COVID-19 VACCINE, ADJUVANTED $140,000 7 payments
  2. Non-Product Specific $60,000 2 payments
  3. KIT COBAS 6800/8800 SARS-COV-2/FLU 384T $20,000 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Infectious Disease: 268

Drug cost

$16,800

Median for Infectious Disease: $217,595

Branded share of claims

0%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Maraviroc Generic 14 $16,800

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$17,387

Of which drugs: $2,855

Medicare patients

54

Average age 74

Services billed

182

33 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 41%
Ischemic heart disease 35%
Diabetes 26%
Depression 26%
Atrial fibrillation 20%
Chronic kidney disease 20%
Cancer 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5ml dosage, for intramuscular use 91304 Office 14 17 $2,561

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

38 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record